These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30663127)

  • 1. Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment.
    Tokuyama M; Shimizu T; Yamada T; Kondoh A; Mabuchi T
    J Dermatol; 2019 Jul; 46(7):e239-e240. PubMed ID: 30663127
    [No Abstract]   [Full Text] [Related]  

  • 2. Psoriasis vulgaris associated with systemic lupus erythematosus successfully treated with apremilast.
    Ichiyama S; Hoashi T; Kanda N; Hashimoto H; Matsushita M; Nozawa K; Ueno T; Saeki H
    J Dermatol; 2019 Jun; 46(6):e219-e221. PubMed ID: 30536461
    [No Abstract]   [Full Text] [Related]  

  • 3. [A case of WPW syndrome complicated with congestive heart failure and atrial fibrillation].
    Nishimura N; Yokoi T; Yamamoto K; Owaki T; Nagamori S
    J Cardiol Suppl; 1989; 22():126-8. PubMed ID: 2640855
    [No Abstract]   [Full Text] [Related]  

  • 4. [Apremilast withdrawals more frequent in standard practice than in clinical trials].
    Schmutz JL
    Ann Dermatol Venereol; 2018 Apr; 145(4):309-310. PubMed ID: 29605438
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of anti-laminin γ1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast.
    Waki Y; Kamiya K; Komine M; Maekawa T; Murata S; Ishii N; Hashimoto T; Ohtsuki M
    Eur J Dermatol; 2018 Jun; 28(3):413-414. PubMed ID: 29619999
    [No Abstract]   [Full Text] [Related]  

  • 7. Galectins for Diagnosis and Prognostic Assessment of Human Diseases: An Overview of Meta-Analyses.
    Liu Y; Meng H; Xu S; Qi X
    Med Sci Monit; 2020 Aug; 26():e923901. PubMed ID: 32744262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Experience With Apremilast in Treating Psoriasis.
    Mayba JN; Gooderham MJ
    J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
    Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Myeloperoxidase, Uric Acid, and the Risk of Atrial Fibrillation in Chronic Kidney Disease.
    Correa S; Curtis KA; Waikar SS; Mc Causland FR
    Circ Arrhythm Electrophysiol; 2021 Apr; 14(4):e009483. PubMed ID: 33858180
    [No Abstract]   [Full Text] [Related]  

  • 11. Improvement in estimated glomerular filtration rate in patients with chronic kidney disease undergoing catheter ablation for atrial fibrillation.
    Navaravong L; Barakat M; Burgon N; Mahnkopf C; Koopmann M; Ranjan R; Kholmovski E; Marrouche N; Akoum N
    J Cardiovasc Electrophysiol; 2015 Jan; 26(1):21-7. PubMed ID: 25142836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
    Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A; Levi E
    J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with apremilast was beneficial for chronic graft-versus-host disease skin lesion in a patient with psoriasis.
    Ichiyama S; Komatsu T; Hoashi T; Kanda N; Nagai K; Yamada Y; Ansai SI; Saeki H
    J Dermatol; 2019 Jun; 46(6):e218-e219. PubMed ID: 30632183
    [No Abstract]   [Full Text] [Related]  

  • 16. Psoriasis increases risk of new-onset atrial fibrillation: a systematic review and meta-analysis of prospective observational studies.
    Upala S; Shahnawaz A; Sanguankeo A
    J Dermatolog Treat; 2017 Aug; 28(5):406-410. PubMed ID: 27794626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast.
    Vazquez B; Gonzalez V; Molina I; Montesinos E; Ramon MD; Monteagudo C
    Clin Exp Dermatol; 2019 Jan; 44(1):66-67. PubMed ID: 29926507
    [No Abstract]   [Full Text] [Related]  

  • 18. Apremilast in psoriasis - a prospective real-world study.
    Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart rate and arrhythmia in patients with psoriasis vulgaris.
    Markuszeski L; Bissinger A; Janusz I; Narbutt J; Jedrzejowska AS; Zalewska A
    Arch Med Res; 2007 Jan; 38(1):64-9. PubMed ID: 17174725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.